行情
BinoNewsBinoNews
首页加密货币股票宏观贵金属行情
加密货币股票宏观贵金属
话题

#ascletis

2 篇报道

#sagimet-biosciences#denifanstat#clinical-trial#biotech#obesity-treatment
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
股票·2周前

Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne

Sagimet Biosciences, the strategic partner of Ascletis Pharma, has successfully dosed the first patient in a pivotal Phase III U.S. clinical trial evaluating denifanstat for moderate to severe acne. This milestone advances the therapeutic candidate closer to potential commercialization.

21548812
Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity
股票·2周前

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

Ascletis reported positive preclinical data for its once-weekly oral peptide pipeline targeting obesity and metabolic disorders. The comprehensive portfolio covers four validated therapeutic targets with potential first-in-class fixed-dose combinations.

20391145
BinoNewsBinoNews

带 AI 影响分析的实时财经新闻网络。

新闻

  • 加密货币
  • 股票
  • 宏观
  • 贵金属

产品

  • 行情
  • 自选列表
  • 账户

公司

  • 隐私政策
  • 使用条款
  • support@binonews.com

BinoNews 是财经新闻聚合平台。所有内容仅供参考,不应被视为投资建议。

BINODEX LIMITED, Company No. 17189151, registered in England and Wales. Registered office: 71-75 Shelton Street, Covent Garden, London WC2H 9JQ, United Kingdom.

© 2026 BINODEX LIMITED. 保留所有权利。

首页行情收藏

我们重视你的隐私. 我们使用必要的 Cookie 来保障网站运行;经你同意后,还会使用分析 Cookie 了解你的阅读偏好并改进网站。